A61P 3 - Drugs for disorders of the metabolism

Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
12/2006
12/28/2006	WO2006138657A1 Bicyclic heterocycles as cannabinoid-1 receptor modulators
12/28/2006	WO2006138656A2 Bicyclic heterocycles as cannabinoid-1 receptor modulators
12/28/2006	WO2006138328A1 Process for the production of antidiabetic oxazolidinediones
12/28/2006	WO2006138038A1 Intralesional treatment of psoriasis
12/28/2006	WO2006137797A1 Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
12/28/2006	WO2006137796A1 Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
12/28/2006	WO2006137795A1 Novel 2-azetidinone derivatives as cholesterol absorption inhibitors useful for the treatment of hyperlipidaemic conditions
12/28/2006	WO2006137794A1 New2-azetidinone derivatives for the treatment of hyperlipidaemic diseases
12/28/2006	WO2006137793A1 New 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
12/28/2006	WO2006137789A1 Quinoline 3 -sulfonate esters as NK3 receptor modulators
12/28/2006	WO2006137782A1 Novel 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia
12/28/2006	WO2006137597A1 Novel physiological substance nesfatin, substance relevant thereto, and use of the substances
12/28/2006	WO2006137527A1 Thiazole derivative
12/28/2006	WO2006137469A1 Metabotropic glutamate receptor activator
12/28/2006	WO2006137450A1 Crystal of phenylalanine derivative, process for producing the same and use thereof
12/28/2006	WO2006137441A1 Anti-fatigue composition
12/28/2006	WO2006137435A1 Agonist to g protein-coupled receptor g2a and method of screening g2a activity controller
12/28/2006	WO2006137314A1 Radial brush
12/28/2006	WO2006137085A1 Genetic variants in the tcf7l2 gene as diagnostic markers for risk of type 2 diabetes mellitus
12/28/2006	WO2006136821A1 Pharmaceutical compounds
12/28/2006	WO2006136502A1 ( 6-FLU0R0-BENZ0[l, 3] DIOXOLYL) -MORPHOLIN-4-YL-METHANONES AND THEIR USE AS CBl LIGANDS
12/28/2006	WO2006136407A1 Process for preparing amorphous rosuvastatin calcium free of impurities
12/28/2006	WO2006136402A1 Thienopyrimidines for pharmaceutical compositions
12/28/2006	WO2006136284A1 Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder
12/28/2006	WO2006136101A1 Glucagon like peptide-1 receptor (glp-1r) regulators, preparation methods and uses
12/28/2006	WO2006136063A1 Aporphine and secoaporphine compounds for treatment of diabetes
12/28/2006	WO2006114284A3 AGONISTIC ANTIBODIES THAT BIND TO THE LT-β-RECEPTOR AND THEREBY MODULATE ADIPOSITY-ASSOCIATED PHENOTYPES AS WELL AS THEIR USE IN THERAPY
12/28/2006	WO2006101521A3 Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
12/28/2006	WO2006099480A3 Stress proteins and peptides and methods of use thereof
12/28/2006	WO2006097536A3 Dimeric peptide agonists of the glp-1 receptor
12/28/2006	WO2006083645A3 Formulations and dosing regimen for ppar-alpha modulators
12/28/2006	WO2006076568A3 Thiazolopyridines as cannabinoid receptor modulators
12/28/2006	WO2006009789A3 Aryl-substituted piperazine derivatives
12/28/2006	WO2005080358A3 Rosiglitazone phosphate and polymorphic forms
12/28/2006	WO2003072714A3 Follistatin domain containing proteins
12/28/2006	US20060293519 Method for producing cyclic diamine derivative or salt thereof
12/28/2006	US20060293507 Crystallization of IGF-1
12/28/2006	US20060293355 Crystalline form of bis [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl] (3r,5s)-3, 5-dihydroxyhept-6-enoicacid] calcium salt
12/28/2006	US20060293348 CSBP/p38 kinase inhibitor; antiinflammatory agent; inflammatory bowel disease; tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, rheumatoid arthritis; 8-(2,4,6-trifluorophenyl)-4-(2,4-difluorophenyl)-2-(2-hydroxy-1-hydroxymethylethylamino)-8H-pyridio[2,3]pyrimidin-7-one
12/28/2006	US20060293347 Pharmaceutically active compounds
12/28/2006	US20060293326 2-Heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases
12/28/2006	US20060293308 Pyridyl derivatives and their use as therapeutic agents
12/28/2006	US20060293299 3-((1S)-1-{1-[(S)-(3-cyanophenyl)(4-cyanophenyl)methyl]azetidin-3-yl}-2-fluoro-2-methylpropyl)-5-fluorobenzonitrile and its salts; antagonists and inverse agonists of the Cannabinoid-1 receptor
12/28/2006	US20060293297 Cyanofluoropyrrolidine derviative
12/28/2006	US20060293256 Remedy or preventive for kidney disease and method of diagnosing kidney disease
12/28/2006	US20060293252 such as 3-(4-Methoxy-phenyl)-1-[3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-thiophen-2-yl]-propan-1-one; for use as antidiabetics
12/28/2006	US20060293239 Treatment and Diagnosis of Insulin-Resistant States
12/28/2006	US20060293225 Gmg-2 polynucleotides and polypeptides and uses thereof
12/28/2006	US20060293223 Uses of melanocortin-3 receptor (mc3r) agonist peptides
12/28/2006	US20060293219 Methods of treating diabetes mellitus
12/28/2006	US20060292648 Screening for target that disrupts interaction between human osteopontin (OPN) and an alpha 4 integrin; inflammatory diseases
12/28/2006	US20060292638 Sequence #115 as a target for identifying weight modulating compounds
12/28/2006	US20060292131 Chondrocyte Therapeutic Delivery System
12/28/2006	CA2655799A1 Thienopyrimidines for pharmaceutical compositions
12/28/2006	CA2633030A1 Intralesional treatment of psoriasis
12/28/2006	CA2613257A1 A novel biological substance nesfatin and its related substances and uses thereof
12/28/2006	CA2613249A1 Crystals of phenylalanine derivatives, production method thereof and use thereof
12/28/2006	CA2613001A1 Quinoline 3 -sulfonate esters as nk3 receptor modulators
12/28/2006	CA2612587A1 Process for preparing amorphous rosuvastatin calcium free of impurities
12/28/2006	CA2612475A1 Genetic variants in the tcf7l2 gene as diagnostic markers for risk of type 2 diabetes mellitus
12/28/2006	CA2612079A1 (6-flu0r0-benz0[1,3] dioxolyl)-morpholin-4-yl-methanones and their use as cb1 ligands
12/28/2006	CA2611823A1 Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
12/28/2006	CA2611142A1 Anti-hypercholesterolemic compounds
12/28/2006	CA2610890A1 Novel 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia
12/28/2006	CA2610036A1 Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
12/28/2006	CA2609994A1 New2-azetidinone derivatives for the treatment of hyperlipidaemic diseases
12/28/2006	CA2609993A1 Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
12/28/2006	CA2609990A1 New 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
12/28/2006	CA2604584A1 Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder
12/27/2006	EP1736775A1 Novel ligand of g protein coupled receptor protein and use thereof
12/27/2006	EP1736541A1 Novel galectin 9 modification protein and use thereof
12/27/2006	EP1736470A2 Pyrimidine derivatives as CB2 cannabinoid receptor modulators
12/27/2006	EP1736467A1 Novel sulfonamide derivative
12/27/2006	EP1736206A1 Physiologically active composition and process for producing the same
12/27/2006	EP1736171A1 Antiobesity drug
12/27/2006	EP1736160A1 Algin oligosaccharides and the derivatives thereof as well as the manufacture and the use of the same
12/27/2006	EP1736158A2 Use of 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiologically acceptable salts
12/27/2006	EP1736150A2 Sertraline salts and sustained-release dosage forms of sertraline
12/27/2006	EP1736149A2 Astaxanthin-containing agent for lowering neutral fat concentration in blood
12/27/2006	EP1735320A1 Compounds and methods for treating dyslipidemia
12/27/2006	EP1735287A1 Therapeutic agents
12/27/2006	EP1735278A1 Histamine h3 receptor agents, preparation and therapeutic uses
12/27/2006	EP1735277A1 2-alkylidene-18,19-dinor-vitamin d compounds
12/27/2006	EP1735275A2 Aryl sulfones and uses related thereto
12/27/2006	EP1735268A1 Opioid receptor antagonists
12/27/2006	EP1734986A1 Method for modulating appetite
12/27/2006	EP1734963A2 Method of treating men with metabolic and anthropometric disorders
12/27/2006	EP1734959A2 Method of treating schizophrenia and/or glucoregulatory abnormalities
12/27/2006	EP1734955A2 Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss
12/27/2006	EP1734953A1 Co-formulations of kits of bioactive agents
12/27/2006	EP1734946A2 Method of using punicic acid to enhance immune response and prevent metabolic disorders
12/27/2006	EP1734930A2 Low dose pharmaceutical products
12/27/2006	EP1608317A4 Dipeptidyl peptidase inhibitors
12/27/2006	EP1554259B1 Novel bicyclic inhibitors of hormone sensitive lipase
12/27/2006	EP1480961B1 Glutaminyl based dpiv inhibitors
12/27/2006	EP1448559B1 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thereof; and its use as pharmaceutical active ingredient
12/27/2006	EP1443925B1 Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
12/27/2006	EP1436267B1 Lactam derivatives as antagonists for human 11cby receptors
12/27/2006	EP1427423B1 Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
12/27/2006	EP1392276B1 Potentiation of therapeutic effects of polyunsaturated fatty acids

1 ... 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 ... 1298